Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
…, A Martin-Nalda, R Colobran, PE Morange… - Science, 2020 - science.org
INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (…
2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (…
[HTML][HTML] DNA methylation and body-mass index: a genome-wide analysis
…, JK Sandling, D Aïssi, S Wahl, E Meduri, PE Morange… - The Lancet, 2014 - thelancet.com
Background Obesity is a major health problem that is determined by interactions between
lifestyle and environmental and genetic factors. Although associations between several …
lifestyle and environmental and genetic factors. Although associations between several …
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
…, M Lambert, V Verdier, PE Morange… - European heart …, 2017 - academic.oup.com
Aims Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic
benefit over clopidogrel after acute coronary syndrome (ACS). However, both drugs are …
benefit over clopidogrel after acute coronary syndrome (ACS). However, both drugs are …
Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation
…, D van Heemst, PE Slagboom, PE Morange… - Nature …, 2021 - nature.com
Characterizing genetic influences on DNA methylation (DNAm) provides an opportunity to
understand mechanisms underpinning gene regulation and disease. In the present study, we …
understand mechanisms underpinning gene regulation and disease. In the present study, we …
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non–ST-segment elevation acute coronary syndrome …
Objectives : We analyzed the benefit of a 600-mg clopidogrel loading dose on platelet
reactivity and clinical outcomes after stenting for non–ST-segment elevation acute coronary …
reactivity and clinical outcomes after stenting for non–ST-segment elevation acute coronary …
Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach
…, M Lathrop, J Emmerich, PE Morange - Blood, The Journal …, 2009 - ashpublications.org
Venous thromboembolism (VTE) is a complex disease that has a major genetic component
of risk. To identify genetic factors that may modify the risk of VTE, we conducted a genome-…
of risk. To identify genetic factors that may modify the risk of VTE, we conducted a genome-…
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors And Clopidogrel …
…, B Gaborit, L Bali, O Brissy, PE Morange… - Journal of the American …, 2009 - jacc.org
Objectives : This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on
platelet response to clopidogrel after coronary stenting for non–ST-segment elevation acute …
platelet response to clopidogrel after coronary stenting for non–ST-segment elevation acute …
[PDF][PDF] Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism
…, DA Trégouët, NL Smith, PE Morange - The American Journal of …, 2015 - cell.com
Venous thromboembolism (VTE), the third leading cause of cardiovascular mortality, is a
complex thrombotic disorder with environmental and genetic determinants. Although several …
complex thrombotic disorder with environmental and genetic determinants. Although several …
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome
Genetic polymorphisms of cytochrome P450 (CYP) isoforms may promote variability in platelet
response to clopidogrel. This study was conducted to analyze, in 603 patients with non–…
response to clopidogrel. This study was conducted to analyze, in 603 patients with non–…
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome
…, L Camoin, J Carvajal, PE Morange… - Thrombosis and …, 2007 - thieme-connect.com
Clopidogrel responsiveness has been proposed to be involved in recurrent ischemic events
after stenting for non-ST elevation acute coronary syndromes (NSTE ACS). However, its …
after stenting for non-ST elevation acute coronary syndromes (NSTE ACS). However, its …